Who are MaxCyte, Inc.'s main suppliers?

MaxCyte, Inc. (MXCT) key suppliers include: ONE-SUPPLIER, SECOND-SUPPLIER, Bio-Rad Laboratories, Inc., Bio-Rad Laboratories, Inc., Precision BioSciences, Inc. and 7 more. View the full supplier network at chainsifter.com/chain/MXCT.

Who are MaxCyte, Inc.'s major customers?

MaxCyte, Inc. (MXCT) key customers include: USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES, USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS, CELL-THERAPY-COMPANY, Precision BioSciences, Inc., Precision BioSciences, Inc. and 17 more. View the full customer network at chainsifter.com/chain/MXCT.

What sector is MaxCyte, Inc. in?

MaxCyte, Inc. (MXCT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

MaxCyte, Inc. Supplier List (MXCT): 12 Verified Suppliers

12Suppliers

22Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

MaxCyte, Inc. (MXCT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

38Total relationships

4Distinct source URLs

14High confidence

0.762Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

MaxCyte, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ONE-SUPPLIER	ONE-SUPPLIER	90%	During the three months ended March 31, 2026 and 2025, 14% and 22% respectively, of the Company's additions to inventory were from one supplier
SECOND-SUPPLIER	SECOND-SUPPLIER	90%	A second supplier accounted for 14% of accounts payable as of March 31, 2026
BIO	Bio-Rad Laboratories, Inc.	72%	doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou…
BIO	Bio-Rad Laboratories, Inc.	72%	Reciprocal relationship from BIO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including…
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not rec…
DTIL	Precision BioSciences, Inc.	72%	ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer…
HBIO	Harvard Bioscience, Inc.	72%	doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou…
HBIO	Harvard Bioscience, Inc.	72%	Reciprocal relationship from HBIO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, includin…
TGTX	TG Therapeutics, Inc.	72%	ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer…
TGTX	TG Therapeutics, Inc.	72%	Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not rec…
TMO	Thermo Fisher Scientific Inc.	72%	Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including…
TMO	Thermo Fisher Scientific Inc.	72%	doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou…

MaxCyte, Inc. Customers

Ticker	Name	Confidence	Evidence
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES	USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES	95%	USAspending awards from Department of Health and Human Services: $181,450 across 2 awards. 75N98026P00164 26-003578 MAXCYTE EXPERT GTX ELECTROPORATION DEVICE AND INSTALLATION/OPERATIONAL QUALIFICATIO…
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS	USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS	95%	USAspending awards from Department of Veterans Affairs: $49,680 across 1 awards. 36C24725P0739 MAXCYTE EXPERT ATX ELECTROPORATION SYSTEM \| Qwen corrected direction: Explicit government contract award…
CELL-THERAPY-COMPANY	CELL-THERAPY-COMPANY	92%	For the year ended December 31, 2025, one cell therapy company with which we have entered into an SPL agreement accounted for 26% of our total revenue
DTIL	Precision BioSciences, Inc.	85%	Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MXCT graph: ory approval for all or any product…
DTIL	Precision BioSciences, Inc.	85%	ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer…
IMUGENE-LIMITED	IMUGENE-LIMITED	85%	pproval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commercial …
TGTX	TG Therapeutics, Inc.	85%	Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: ory approval for all or any product…
TGTX	TG Therapeutics, Inc.	85%	ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commer…
BIO	Bio-Rad Laboratories, Inc.	72%	Reciprocal relationship from BIO graph: Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including…
BIO	Bio-Rad Laboratories, Inc.	72%	doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou…
HBIO	Harvard Bioscience, Inc.	72%	Reciprocal relationship from HBIO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from HBIO g…
HBIO	Harvard Bioscience, Inc.	72%	doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou…
TMO	Thermo Fisher Scientific Inc.	72%	doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and ou…
TMO	Thermo Fisher Scientific Inc.	72%	Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO grap…
ALTHOUGH-PRECISION-BIOSCIENCES-INC	ALTHOUGH-PRECISION-BIOSCIENCES-INC	62%	pproval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial milestone payments or the sales-based commercial …
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	by $0.1 million, or 2%, for the year ended December 31, 2025, compared to the year ended December 31, 2024. Interest Income Year Ended December 31, Change 2025 …
CRS	Carpenter Technology Corporation	62%	Reciprocal relationship from CRS graph: Reciprocal relationship from MXCT graph: by $0.1 million, or 2%, for the year ended December 31, 2025, compared to the year ended December 31, 2024. Interest I…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	erating activities to compliance 68 Table of Contents activities. It could also make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability …
HARVARD-BIOSCIENCES-INC	HARVARD-BIOSCIENCES-INC	62%	ships with multiple custom parts manufacturers and electronics suppliers that can provide components for our instruments, including components currently provided by a single source. Approximately 13%…
LONZA-GROUP-AG-THERMO-FISHER-SCIENTIFIC-INC	LONZA-GROUP-AG-THERMO-FISHER-SCIENTIFIC-INC	62%	ts. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and our ability to execute …
MILTENYI-BIOTEC-BIO-RAD-LABORATORIES-INC	MILTENYI-BIOTEC-BIO-RAD-LABORATORIES-INC	62%	ships with multiple custom parts manufacturers and electronics suppliers that can provide components for our instruments, including components currently provided by a single source. Approximately 13%…
TMO-MILTENYI-BIOTEC-BIO-RAD-LABORATORIES-INC	TMO-MILTENYI-BIOTEC-BIO-RAD-LABORATORIES-INC	62%	ts. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products may be slowed and our ability to execute …

MaxCyte, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
MXCT-DEBT	Debt stack $17.5M	90%	Market cache reports total debt of $17.5M.
MXCT-DEBT-11143	Warrants outstanding: 71168	90%	xbrl warrant detail from xbrl 2021-12-31.
MXCT-DEBT-11144	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

MaxCyte, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for MaxCyte, Inc..

MaxCyte, Inc. Ownership

Holder	Name	Confidence	Evidence
MXCT-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 131 tracked holders.

MaxCyte, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
IMTX	Immatics N.V.	100.00	2
SOLV	Solventum Corporation	100.00	2
ICLR	ICON Public Limited Company	100.00	2
GH	Guardant Health, Inc.	100.00	2
TWST	Twist Bioscience Corporation	100.00	2
MGX	Metagenomi Therapeutics, Inc.	100.00	2
CLLS	Cellectis S.A.	100.00	2
HBIO	Harvard Bioscience, Inc.	100.00	1	['customer', 'supplier']
IDXG	Interpace Biosciences, Inc.	100.00	2
FISI	Financial Institutions, Inc.	100.00	2
TGTX	TG Therapeutics, Inc.	100.00	1	['customer', 'supplier']
AZTA	Azenta, Inc.	100.00	2
BDX	Becton, Dickinson and Company	100.00	2
BTAI	BioXcel Therapeutics, Inc.	100.00	2
CRS	Carpenter Technology Corporation	100.00	1	['customer']
BHPLF	BHP Group Limited	100.00	2
BIO	Bio-Rad Laboratories, Inc.	100.00	1	['customer', 'supplier']
CELU	Celularity Inc.	100.00	2
FBIO	Fortress Biotech, Inc.	100.00	2
BHP	BHP Group Limited	100.00	2

MaxCyte, Inc. Supply Chain